a target dose of 30 or 60 µg.

In patients with type 2 diabetes, the starting dose is 60 µg before meals, which can be increased to 120 µg if there has been no nausea for 3 to 7 days.

In either type of diabetes, the insulin dose is adjusted to achieve optimal glycemic control after the pramlintide dosage is stable.

Symlin is available in vial form, but since many injectable compounds for diabetes come in pen form, it is reasonable to assume this delivery device may be available in the future.

**REFERENCES**


**ADDRESS:** Byron J. Hoogwerf, MD, Department of Endocrinology, Diabetes, and Metabolism, A53, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail hoogweb@ccf.org.